middl
east
respiratori
syndrom
coronaviru
merscov
continu
threat
human
health
middl
east
develop
countermeasur
ongo
howev
anim
model
faith
recapitul
human
diseas
yet
defin
recent
studi
indic
inocul
common
marmoset
result
inconsist
lethal
base
data
sought
compar
two
isol
merscov
follow
diseas
progress
common
marmoset
intratrach
exposur
media
inactiv
viru
data
suggest
common
marmoset
develop
mild
moder
nonleth
respiratori
diseas
quantifi
comput
tomographi
ct
limit
clinic
sign
base
ct
data
clinic
data
virolog
data
merscov
inocul
common
marmoset
result
mild
moder
clinic
sign
diseas
like
due
manipul
marmoset
rather
result
robust
viral
replic
publish
elsevi
inc
infect
middl
east
respiratori
syndrom
coronaviru
merscov
associ
middl
east
respiratori
syndrom
commonli
known
mer
respiratori
syndrom
acut
sever
hypox
respiratori
failur
often
accompani
renal
failur
arabi
et
al
assiri
et
al
zaki
et
al
march
approxim
laboratori
confirm
case
report
case
fatal
rate
http
wwwwhointcsrdiseasecoronavirusinfect
consid
geograph
locat
mer
hajj
pilgrimag
draw
estim
million
visitor
roughli
million
travel
intern
http
wwwcdsigovsaenglish
indexphp
optioncomdocman
merscov
repres
global
health
risk
common
sign
symptom
mer
includ
fever
cough
short
breath
myalgia
gastrointestin
sign
also
frequent
observ
includ
vomit
diarrhea
abdomin
pain
assiri
et
al
often
mer
patient
also
underli
comorbid
diabet
hypertens
chronic
cardiac
renal
diseas
assiri
et
al
guid
develop
mer
countermeasur
appropri
anim
model
must
identifi
character
ideal
laboratori
anim
model
would
demonstr
clinic
sign
consist
aspect
human
diseas
infecti
diseas
mice
evalu
potenti
mer
model
pathogenesi
countermeasur
screen
balbc
knockout
mice
develop
sign
diseas
weight
loss
could
infecti
viru
recov
lung
homogen
coleman
et
al
zhao
et
al
develop
murin
model
mer
transduct
respiratori
tract
put
merscov
receptor
human
dipeptidyl
peptidas
use
adenoviru
construct
zhao
et
al
infect
mice
develop
limit
clinic
sign
includ
small
degre
weight
loss
histopatholog
analysi
found
peribronchi
perivascular
lymphoid
infiltr
later
progress
interstiti
pneumonia
nearli
log
plaqu
form
unit
pfu
g
infecti
viru
could
detect
lung
infect
transduc
mice
zhao
et
al
transduc
mous
model
use
evalu
countermeasur
pathogenesi
channappanavar
et
al
channappanavar
et
al
nonhuman
primat
nhp
model
consid
essenti
understand
pathogenesi
evalu
countermeasur
result
sever
challeng
studi
merscov
rhesu
monkey
macaca
mulatta
vari
laboratori
first
publish
nhp
model
use
rhesu
monkey
inocul
via
multipl
rout
evalu
virolog
immunolog
histopatholog
chang
day
postinocul
nhp
demonstr
sign
pneumonia
viru
could
detect
tissu
mucou
membran
quantit
revers
transcriptas
polymeras
chain
reaction
qrtpcr
attempt
determin
load
infecti
viru
report
follow
studi
demonstr
administr
ribavirin
reduc
viral
burden
lessen
diseas
result
natur
histori
studi
merscovinfect
rhesu
monkey
indic
intratrach
inocul
induc
nonleth
diseas
limit
patholog
observ
recov
anim
day
postinocul
infecti
viru
could
recov
lung
tissu
assay
yao
et
al
standard
radiolog
examin
reveal
lung
infiltr
day
postinocul
suggest
virusinduc
lung
diseas
recent
falzarano
et
al
describ
multipl
rout
inocul
common
marmoset
callithrix
jacchu
transcript
chang
indic
induct
immun
inflammatori
repair
pathway
catalog
partial
lethal
observ
falzarano
et
al
character
intratrach
inocul
merscov
common
marmoset
model
mer
determin
differ
two
common
isol
merscov
viru
viru
inocul
group
marmoset
follow
diseas
progress
period
physic
exam
includ
comput
tomographi
ct
previous
positron
emiss
tomographi
comput
tomographi
pet
ct
use
evalu
tuberculosi
therapi
common
marmoset
via
et
al
diseas
progress
monkeypoxvirusinocul
cynomolgu
monkey
dyall
et
al
influenzaavirusinocul
ferret
jonsson
et
al
ct
two
distinct
advantag
compar
standard
xray
radiographi
ct
provid
three
dimension
data
ct
data
quantifi
allow
unbias
comparison
elk
et
al
li
et
al
romanova
et
al
exvivo
experi
marmoset
lung
kidney
primari
cultur
found
tissu
could
support
merscov
replic
suggest
common
marmoset
might
develop
suitabl
anim
model
mer
fig
therefor
sought
determin
intratrach
inocul
marmoset
would
result
diseas
present
similar
human
diseas
experiment
design
shown
fig
two
preinocul
baselin
ct
perform
establish
normal
lung
volum
preexist
anomali
viru
mersjor
genbank
viru
mersemc
genbank
obtain
propag
describ
materi
method
ensur
gross
crosscontamin
merscov
stock
use
marmoset
experi
occur
prepar
spike
protein
stock
sequenc
compar
refer
sequenc
cotten
et
al
frey
et
al
spike
region
chosen
comparison
due
high
divers
associ
viral
glycoprotein
strainspecif
differ
found
mersjor
mersemc
refer
sequenc
maintain
stock
tabl
indic
gross
crosscontamin
occur
three
singl
nucleotid
polymorph
snp
seen
stock
two
mersemc
one
mersjor
blastx
align
indic
two
snp
lead
chang
protein
sequenc
mersjor
stock
c
chang
posit
induc
chang
two
chang
observ
mersemc
c
posit
alter
amino
acid
sequenc
c
chang
result
chang
chang
region
seen
like
result
serial
passag
cell
cultur
frey
et
al
bodi
temperatur
peripher
oxygen
satur
respiratori
rate
overal
condit
evalu
physic
exam
increas
bodi
temperatur
normal
rang
observ
subject
maintain
peripher
oxygen
throughout
studi
respiratori
rate
increas
normal
rang
sporad
throughout
studi
fig
tremor
note
daili
observ
includ
day
postinocul
consist
observ
data
shown
subject
underw
blood
withdraw
day
necropsi
determin
hematolog
paramet
indic
chang
consist
diseas
day
chosen
base
data
mersjor
inocul
rhesu
monkey
demonstr
peak
lung
diseas
day
postinocul
ct
manuscript
prepar
subject
develop
clinic
signific
chang
total
white
blood
cell
count
lymphocyt
number
monocyt
number
neutrophil
number
day
postinocul
remain
within
normal
rang
indic
shade
gray
area
fig
togeth
data
indic
subject
develop
system
clinic
diseas
determin
viru
dissemin
shed
whole
blood
oropharyng
rectal
swab
fecal
sampl
mock
inactiv
viru
subject
subject
per
group
collect
day
mer
jordan
subject
exvivo
analysi
primari
cell
cell
isol
lung
kidney
bronchoalveolar
lavag
bal
onestep
growth
kinet
perform
describ
materi
method
lung
kidney
bal
demonstr
merscov
abl
replic
least
log
pfuml
swab
day
n
n
n
n
n
n
n
mersemc
expos
subject
swab
day
n
n
n
n
n
n
outlin
fig
sampl
assay
qrtpcr
describ
materi
method
sampl
neg
merscov
suggest
viru
dissemin
shed
furthermor
plaqu
assay
perform
necropsi
tissu
infecti
viru
could
detect
viru
isol
attempt
use
lung
homogen
two
sequenti
passag
vero
cell
infecti
viru
could
detect
fluoresc
reduct
neutral
assay
perform
determin
marmoset
develop
antibodi
respons
merscov
fig
subject
inocul
mersjor
develop
low
antibodi
titer
merscov
averag
titer
across
group
studi
end
day
postinocul
anim
inocul
mersemc
develop
antibodi
titer
subject
media
inactiv
viru
develop
detect
neutral
antibodi
respons
merscov
qualit
assess
imag
data
indic
merscov
inocul
marmoset
develop
lung
diseas
mainli
affect
medial
caudal
region
lung
lung
abnorm
could
observ
mediaonli
inactiv
viru
inocul
group
inactiv
viru
stimul
increas
lung
abnorm
compar
media
mock
inocul
subject
fig
lung
infiltr
present
air
bronchogram
complet
clear
end
studi
fig
importantli
quantit
assess
abnorm
lung
volum
data
support
qualit
assess
quantit
assess
suggest
mock
inocul
subject
develop
short
live
respons
observ
one
day
postinocul
return
near
baselin
day
ct
remain
near
volum
throughout
cours
studi
subject
inocul
inactiv
viru
demonstr
increas
abnorm
lung
volum
compar
media
group
elev
group
receiv
live
viru
merscov
inocul
group
demonstr
increasingli
abnorm
lung
volum
begin
day
postinocul
individu
depend
manner
complet
resolv
studi
end
fig
comparison
mean
peak
valu
diseas
lung
volum
percent
rel
chang
abnorm
lung
volum
group
indic
statist
signific
differ
unpair
ttest
viru
isol
fig
f
peak
diseas
lung
volum
infecti
mersemc
receiv
group
compar
mock
infect
pvalu
compar
viru
receiv
group
p
comparison
mersjor
group
control
group
indic
similar
pattern
p
p
respect
comparison
fold
chang
diseas
lung
volum
mersemc
mock
group
gave
p
viru
receiv
group
comparison
fold
chang
diseas
lung
volum
mersjor
mock
group
gave
p
p
data
indic
common
marmoset
genet
sequenc
differ
isol
impact
diseas
progress
indic
chang
diseas
lung
volum
mer
virion
induc
inflammatori
respons
howev
signific
differ
observ
mersemc
group
mock
expos
group
compar
fold
chang
diseas
lung
volum
like
reflect
small
group
size
differ
tempor
progress
observ
individu
subject
segreg
viru
isol
one
subject
mersemc
inocul
group
appear
develop
secondari
infect
observ
ct
increas
studi
end
day
postexposur
howev
infecti
viru
could
recov
suggest
opportunist
infect
either
due
repeat
manipul
effect
merscov
necropsi
lung
lesion
includ
multifoc
coalesc
interstiti
pneumonia
consolid
dorsocaud
lung
lobe
merscov
inocul
anim
fig
gross
patholog
merscov
infect
subject
reveal
moder
chang
chang
includ
interstiti
multifoc
coalesc
moder
pneumonia
shown
fig
histopatholog
examin
select
lymphoid
tissu
reveal
mild
lymphoid
hyperplasia
medullari
histiocytosi
mandibular
tracheobronchi
lymph
node
sever
merscov
inocul
subject
control
anim
show
minim
chang
examin
repres
lung
tissu
sampl
show
interstiti
lymphohistiocyt
pneumonia
type
ii
pneumocyt
bronchial
associ
lymphoid
tissu
balt
hyperplasia
syncytia
observ
merscov
inocul
anim
fig
addit
lung
lesion
observ
merscov
inocul
subject
consist
chronic
respiratori
diseas
gener
gross
histopatholog
find
lung
tissu
somewhat
correspond
ct
find
examin
repres
lung
tissu
singl
subject
receiv
mersjor
demonstr
greatest
increas
diseas
lung
volum
seen
ct
differ
grossli
histolog
subject
signal
detect
presenc
merscov
antigen
immunohistochemistri
ihc
perform
lung
tissu
section
infect
subject
ideal
anim
model
mer
recapitul
key
featur
human
diseas
sever
form
therefor
ideal
mer
model
might
result
lethal
diseas
sever
bronchopneumonia
extrapulmonari
complic
renal
failur
use
ct
observ
inocul
common
marmoset
mersjor
mersemc
isol
result
nonleth
diseas
character
limit
clinic
sign
moder
consolid
lung
patholog
complet
resolv
studi
end
differ
clinic
sign
observ
two
isol
control
subject
could
detect
merscov
genom
use
genom
specif
qrtpcr
assay
sensit
genom
copi
merscov
detect
neutral
antibodi
infecti
viru
receiv
group
viru
receiv
group
suggest
infecti
process
take
place
allow
antigen
process
develop
neutral
antibodi
artifact
introduc
manipul
subject
account
use
control
subject
control
marmoset
inocul
media
inactiv
viru
also
result
limit
lung
patholog
present
studi
examin
percent
chang
diseas
lung
volum
determin
signific
differ
observ
mersemc
group
mock
group
mersemc
group
suggest
viralinduc
diseas
process
occur
howev
statist
signific
found
total
diseas
lung
volum
compar
group
across
group
patholog
find
predominantli
confin
lung
show
chronic
resolv
chang
absenc
viral
antigen
signal
lung
tissu
section
ihc
might
result
probe
viral
antigen
late
stage
diseas
like
consider
clearanc
viru
falzarano
et
al
observ
inconsist
lethal
highlight
lung
patholog
share
characterist
mer
follow
mersemc
exposur
common
marmoset
three
notabl
differ
present
studi
falzarano
et
al
use
control
subject
receiv
media
inactiv
viru
singl
rout
vs
multipl
inocul
rout
oral
intranas
ocular
volum
lung
inoculum
ml
vs
ml
similar
rhesu
experi
marmoset
experi
design
serial
euthanasia
studi
six
subject
euthan
earli
timepoint
postexposur
diseas
cours
could
resolv
howev
two
subject
met
moribund
endpoint
criteria
day
surviv
day
postinocul
unknown
true
outcom
subject
serial
euthan
would
subject
met
endpoint
criteria
due
viru
induc
diseas
subject
manipul
thu
skew
interpret
diseas
sever
ad
difficulti
data
interpret
qrtpcr
data
support
immunohistochemistri
em
viru
isol
furthermor
pattern
infecti
viru
isol
shown
falzarano
et
al
demonstr
initi
lung
contain
infecti
viru
tissu
trachea
lung
lobe
examin
day
postinocul
viru
isol
fewer
lung
lobe
tissu
viru
isol
trachea
day
postinocul
viru
detect
lung
lobe
trachea
examin
quantif
provid
therefor
difficult
determin
propag
infecti
viru
recov
mere
inoculum
base
data
falzarano
et
al
data
possibl
intratrach
inocul
result
mechan
damag
respiratori
epithelium
follow
inflamm
repair
lead
restor
mucociliari
motion
clear
liquid
viru
lung
absenc
lethal
model
quantit
measur
becom
valuabl
demonstr
pathogenesi
present
studi
demonstr
ct
effect
evalu
diseas
progress
regress
follow
mer
cov
exposur
common
marmoset
ct
data
quantifi
provid
opportun
effect
evalu
countermeasur
suboptim
model
strengthen
data
gain
wellestablish
model
case
mer
optim
anim
model
must
still
develop
stage
euthanasia
studi
similar
adenoviru
transduc
mous
mer
model
could
perform
nhp
studi
undesir
due
ethic
concern
nonhuman
primat
use
vero
cell
atcc
catalog
number
maintain
dulbecco
modifi
eagl
medium
dmem
hyclon
logan
ut
supplement
fetal
bovin
serum
fb
sigma
st
loui
mo
co
merscov
isol
propag
multipl
infect
vero
cell
fb
co
day
postinocul
cytopath
effect
encompass
vero
cell
monolay
viru
concentr
ultracentrifug
pellet
sucros
cushion
g
h
pellet
resuspend
dmem
fb
frozen
titer
limit
dilut
plaqu
assay
see
inactiv
viru
control
group
gener
treat
viru
gy
gamma
irradi
cobalt
irradi
jl
shepherd
follow
confirm
inactiv
kind
gift
arm
forc
health
surveil
center
divis
global
emerg
infect
surveil
respons
system
kindli
provid
vincent
munster
laboratori
virolog
nation
institut
allergi
infecti
diseas
niaid
marmoset
lung
tissu
ground
steril
petri
dish
use
plunger
steril
syring
digest
uml
collagenas
life
technolog
ny
usa
fetal
calf
serum
fc
hyclon
min
reaction
quench
homogen
pass
filter
wash
centrifug
g
min
final
wash
cell
resuspend
ml
ack
lyse
buffer
life
technolog
min
wash
twice
ml
mm
bsa
wash
pellet
cell
resuspend
rpmi
lonza
switzerland
supplement
fc
hyclon
ut
usa
penicillinstreptomycin
ps
plate
media
chang
h
kidney
process
similar
lung
strain
mm
mm
filter
prior
ack
lysi
step
bronchoalveolar
lavag
sampl
centrifug
g
min
resuspend
rpmi
fc
ps
life
technolog
plate
multistep
growth
curv
perform
isol
primari
cell
infect
mersjor
multipl
infect
supernat
harvest
h
store
plaqu
assay
perform
describ
merscov
isol
sequenc
use
primer
tabl
spike
genom
sequenc
gener
align
sanger
gener
comparison
studi
stock
refer
spike
sequenc
obtain
sequenc
associ
refer
sequenc
align
use
clustal
omega
default
set
goujon
et
al
mcwilliam
et
al
siever
et
al
result
clustal
align
filter
align
posit
least
one
variant
base
use
custom
python
script
potenti
code
chang
assess
blastx
align
altschul
et
al
ten
common
marmoset
rang
weight
g
g
age
year
divid
group
mock
inocul
subject
n
receiv
dmem
supplement
fb
inocul
two
subject
receiv
inactiv
viru
inocul
one
subject
receiv
inactiv
mersjor
viru
isol
one
subject
receiv
inactiv
mersemc
viru
isol
three
marmoset
receiv
pfu
mersjor
other
receiv
pfu
mersemc
inocul
prior
handl
marmoset
anesthet
isofluran
effect
inocul
perform
placement
gaug
cathet
trachea
follow
instal
viru
inoculum
ml
volum
follow
ml
air
flush
syring
cathet
anim
procedur
approv
nation
institut
allergi
infecti
diseas
niaid
anim
care
use
committe
adher
nation
institut
health
nih
polici
experi
carri
niaid
integr
research
facil
aaalac
aala
accredit
facil
prior
inocul
ct
scan
physic
exam
includ
temperatur
weight
measur
perform
oropharyng
rectal
swab
stool
sampl
collect
fig
nhp
monitor
least
twice
daili
preestablish
scale
use
evalu
subject
health
diseas
progress
criteria
includ
overal
clinic
appear
labor
breath
activ
behavior
respons
core
bodi
temperatur
subject
met
moribund
clinic
endpoint
criteria
studi
end
eight
marmoset
human
euthan
histopatholog
virolog
analysi
blood
withdraw
perform
preinocul
either
day
postinocul
necropsi
acquir
high
resolut
chest
ct
scan
without
contrast
use
hybrid
philip
gemini
slice
petct
scanner
specif
design
function
biolog
safeti
level
environ
due
rapid
respiratori
rate
marmoset
breath
hold
could
perform
ct
paramet
follow
helic
scan
kvp
mm
field
view
mmrotat
tabl
speed
highresolut
collim
mm
mm
slice
thick
mm
increment
cover
whole
lung
imag
acquir
use
standard
algorithm
reconstruct
use
ydetail
algorithm
imag
analyz
previous
describ
via
et
al
unpair
ttest
peak
abnorm
lung
volum
perform
graphpad
prism
graphpad
softwar
ca
usa
complet
blood
cell
differenti
count
determin
blood
sampl
collect
edtaco
blood
tube
analyz
use
sysmex
hematolog
analyz
sysmex
america
viral
load
sampl
determin
quantit
pcr
use
follow
primer
probe
set
forward
primer
gtggtggttatcact
revers
primer
probe
cycl
condit
min
min
rtstep
follow
cycl
taqman
onestep
rtpcr
master
mix
use
life
technolog
ny
usa
sampl
extract
trizol
screen
presenc
merscov
use
specif
primer
appli
biosystem
fast
real
time
pcr
system
life
technolog
limit
detect
gene
copi
viru
stock
tissu
sampl
excis
necropsi
flash
frozen
store
tissu
wv
homogen
gener
serial
dilut
made
viru
stock
growth
curv
sampl
tissu
incub
confluent
cell
use
tragacanth
emem
fb
ps
overlay
incub
day
follow
incub
tragacanth
overlay
remov
monolay
stain
crystal
violet
crystal
violet
ethanol
formalin
vv
plaqu
enumer
serum
sampl
taken
necropsi
experi
end
heat
inactiv
h
serial
dilut
mix
pfu
final
either
mersjor
mersemc
incub
h
incub
viru
serum
mixtur
ad
cell
atcc
manassa
va
h
co
well
operetta
perkinelm
compat
plate
neg
control
viru
serum
sampl
posit
control
viru
rabbit
polyclon
antibodi
mer
spike
protein
sino
biolog
sampl
also
includ
cell
wash
incub
h
follow
fixat
nbf
merscov
infect
visual
fluoresc
use
merscov
antispik
antibodi
sino
biolog
operetta
high
content
imag
perkinelm
dilut
inhibit
rel
fluoresc
intens
observ
report
frna
fortyon
tissu
major
organ
system
collect
fix
neutral
buffer
formalin
nbf
day
follow
fixat
nbf
tissu
process
follow
standard
procedur
hematoxylin
eosin
stain
appli
use
leica
autom
stain
system
leica
microsystem
stain
slide
examin
via
standard
light
microscopi
detect
merscov
antigen
ihc
perform
use
rabbit
polyclon
antiserum
merscov
sino
biolog
pr
china
tissu
uninfect
control
anim
use
valid
ihc
procedur
ihc
section
examin
light
microscopi
veterinari
pathologist
sy
lh
experi
sought
determin
viru
specif
differ
diseas
progress
follow
intratrach
inocul
common
marmoset
middl
eastern
respiratori
syndrom
coronaviru
commonli
known
merscov
two
common
laboratori
viral
isol
mersemc
mersjordan
contrast
previou
result
observ
nonleth
diseas
sign
virusspecif
patholog
addit
unabl
isol
infecti
viru
tissu
comput
tomographi
use
evalu
diseas
progress
provid
quantit
data
comparison
mockexpos
inactiv
virusexpos
virusexpos
subject
data
indic
marmoset
faith
replic
human
mer
pathogenesi
altern
model
must
develop
efficaci
test
medic
countermeasur
